Danika L. Lew

4.3k total citations · 1 hit paper
72 papers, 2.8k citations indexed

About

Danika L. Lew is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Danika L. Lew has authored 72 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 26 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Danika L. Lew's work include Cancer Treatment and Pharmacology (26 papers), Breast Cancer Treatment Studies (18 papers) and HER2/EGFR in Cancer Research (14 papers). Danika L. Lew is often cited by papers focused on Cancer Treatment and Pharmacology (26 papers), Breast Cancer Treatment Studies (18 papers) and HER2/EGFR in Cancer Research (14 papers). Danika L. Lew collaborates with scholars based in United States, Canada and South Africa. Danika L. Lew's co-authors include Julie R. Gralow, Robert B. Livingston, Gabriel N. Hortobágyi, William E. Barlow, Daniel F. Hayes, Kathy S. Albain, Shaker R. Dakhil, Anne F. Schott, Joseph M. Unger and Dawn L. Hershman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Danika L. Lew

70 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500

2014 482 citations William E. Barlow, Gabriel N. Hortobágyi et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Danika L. Lew

Since Specialization

Citations

This map shows the geographic impact of Danika L. Lew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danika L. Lew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danika L. Lew more than expected).

Fields of papers citing papers by Danika L. Lew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danika L. Lew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danika L. Lew. The network helps show where Danika L. Lew may publish in the future.

Co-authorship network of co-authors of Danika L. Lew

This figure shows the co-authorship network connecting the top 25 collaborators of Danika L. Lew. A scholar is included among the top collaborators of Danika L. Lew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danika L. Lew. Danika L. Lew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222 2021 ·Clinical Cancer Research ·Halle C. F. Moore, William E. Barlow, George Somlo, Julie R. Gralow, Anne F. Schott, Daniel F. Hayes, Peter Kühn, James Hicks, Lisa Welter, (unknown), Christina Yeon, Alison Conlin, Ernie Balcueva, Danika L. Lew, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobágyi	8
2	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812) 2019 ·Cancer Prevention Research ·Katherine D. Crew, Garnet L. Anderson, Dawn L. Hershman, Mary Beth Terry, Parisa Tehranifar, Danika L. Lew, Monica Yee, Eric Brown, (unknown), (unknown), Therese B. Bevers, John E. Doster, Corrine Zarwan, Laura Kruper, Lori M. Minasian, Leslie G. Ford, Banu Arun, Marian L. Neuhouser, Gary E. Goodman, Powel H. Brown	16
3	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer 2019 ·New England Journal of Medicine ·Rita S. Mehta, William E. Barlow, Kathy S. Albain, Ted Vandenberg, Shaker R. Dakhil, (unknown), Danika L. Lew, Daniel F. Hayes, Julie R. Gralow, Hannah M. Linden, Robert B. Livingston, Gabriel N. Hortobágyi	78
4	Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202 2017 ·Journal of Clinical Oncology ·N. Lynn Henry, Joseph M. Unger, Anne F. Schott, Louis Fehrenbacher, Patrick J. Flynn, Debra M. Prow, (unknown), Gary V. Burton, Charles Kuzma, Anna Moseley, Danika L. Lew, Michael Fisch, Carol M. Moinpour, Dawn L. Hershman, James L. Wade	70
5	SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer 2016 ·Breast Cancer Research and Treatment ·Zeina Nahleh, William E. Barlow, Daniel F. Hayes, Anne F. Schott, Julie R. Gralow, William M. Sikov, Edith A. Perez, (unknown), Hamid Mirshahidi, (unknown), Danika L. Lew, Lajos Pusztai, Robert B. Livingston, Gabriel N. Hortobágyi	62
6	Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). 2015 ·Journal of Clinical Oncology ·(unknown), William E. Barlow, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Peter Ganz, Eleftherios P. Mamounas, Soonmyung Paik, Hanna Bandos, Julie R. Gralow, Danika L. Lew, Gabriel N. Hortobágyi	7
7	Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients 2015 ·Journal of Acupuncture and Meridian Studies ·Heather Greenlee, Katherine D. Crew, Jillian L. Capodice, Danielle Awad, (unknown), Joseph M. Unger, Danika L. Lew, Lisa Hansen, Frank L. Meyskens, James L. Wade, Dawn L. Hershman	7
8	SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. 2014 ·Journal of Clinical Oncology ·Julie R. Gralow, William E. Barlow, Alexander Paterson, Danika L. Lew, Alison Stopeck, Daniel F. Hayes, Dawn L. Hershman, Mark Schubert, Mark Clemons, Catherine Van Poznak, Elizabeth Claire Dees, James N. Ingle, Carla I. Falkson, Anthony Elias, Michael J. Messino, Jeffrey Margolis, Shaker R. Dakhil, Helen K. Chew, Robert B. Livingston, Gabriel N. Hortobágyi	9
9	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy 2013 ·Journal of Clinical Oncology ·Dawn L. Hershman, Joseph M. Unger, Katherine D. Crew, Lori M. Minasian, Danielle Awad, Carol M. Moinpour, Lisa Hansen, Danika L. Lew, Heather Greenlee, Louis Fehrenbacher, James L. Wade, Siu‐Fun Wong, Gabriel N. Hortobágyi, Frank L. Meyskens, Kathy S. Albain	145
10	A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102 2013 ·Breast Cancer Research and Treatment ·Julie R. Gralow, William E. Barlow, Danika L. Lew, (unknown), George Somlo, Kristine Rinn, (unknown), Lucas Wong, Robert B. Livingston, Gabriel N. Hortobágyi	0
11	S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. 2013 ·Journal of Clinical Oncology ·G. Thomas Budd, William E. Barlow, Halle C. F. Moore, Timothy J. Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, (unknown), Kristine Rinn, Kathy S. Albain, Helen K. Chew, Gary V. Burton, Timothy D. Moore, Gordan Srkalović, Bradley A. McGregor, Lawrence E. Flaherty, Robert B. Livingston, Danika L. Lew, Julie R. Gralow, Gabriel N. Hortobágyi	8
12	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer 2012 ·New England Journal of Medicine ·Rita S. Mehta, William E. Barlow, Kathy S. Albain, Ted Vandenberg, Shaker R. Dakhil, (unknown), Danika L. Lew, Daniel F. Hayes, Julie R. Gralow, Robert B. Livingston, Gabriel N. Hortobágyi	278
13	SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer 2011 ·Breast Cancer Research and Treatment ·Robert B. Livingston, William E. Barlow, Joseph J. Kash, Kathy S. Albain, Julie R. Gralow, Danika L. Lew, Lawrence E. Flaherty, Melanie Royce, Gabriel N. Hortobágyi	4
14	Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012) 2009 ·Breast Cancer Research and Treatment ·Marilyn L. Slovak, Victoria Bedell, Danika L. Lew, Kathy S. Albain, Georgiana K. Ellis, Robert B. Livingston, Silvana Martino, Edith A. Perez, Gabriel N. Hortobágyi, Dorie Sher, Wendy Stock	12
15	Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528 2009 ·Journal of Clinical Oncology ·Christine Hoban, Antje Hoering, Timothy W. Synold, Vincent Chung, David R. Gandara, Anne F. Schott, Laura Kingsbury, Danika L. Lew, Patricia LoRusso, Shirish M. Gadgeel	2
16	A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338 2008 ·Clinical Breast Cancer ·Helen K. Chew, William E. Barlow, Kathy S. Albain, Danika L. Lew, Allen M. Gown, Daniel F. Hayes, Julie R. Gralow, Gabriel N. Hortobágyi, Robert B. Livingston	31
17	Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), Kathy S. Albain, Julie R. Gralow, Danika L. Lew, Lawrence E. Flaherty, Melanie Royce, G. N. Hortobágyi, R. B. Livingston	2
18	Phase II Trial of Recombinant Human Interleukin-4 in Patients With Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study 2002 ·Journal of Immunotherapy ·Robert P. Whitehead, Danika L. Lew, Robert C. Flanigan, Geoffrey R. Weiss, Vivek Roy, Michael Glodé, Shaker R. Dakhil, E. David Crawford	39
19	Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study 1998 ·Investigational New Drugs ·Wolfram E. Samlowski, Danika L. Lew, Philip Kuebler, Michael Kolodziej, Jesús E. Medina, Kenneth F. Mangan, (unknown), (unknown), John F. Ensley	6
20	Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124) 1998 ·Investigational New Drugs ·Frederick J. Meyers, Danika L. Lew, Primo N. Lara, Steve Williamson, Ernest Marshall, Stanley P. Balcerzak, Saul E. Rivkin, Wolfram E. Samlowski, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact